PD-L1 Antibody (YA4674)

Cat. No.: HY-P84982: Data Sheet COA
SDS
User Guide for Antibodies
FAQs
Technical Support

PD-L1 Antibody (YA4674) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

For research use only. We do not sell to patients.

Size	Stock	Quantity
10 μL	In-stock	Estimated Time of Arrival: December 31
50 μL	In-stock	Estimated Time of Arrival: December 31
100 μL	Get quote	Estimated Time of Arrival: December 31
250 μL	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

1 Publications Citing Use of MCE PD-L1 Antibody (YA4674)

•SSRN. 2025 Nov 3.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Verification Image
Background
Documentation

Description

PD-L1 Antibody (YA4674) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PD-L1.

Host

Rabbit

Clonality

Monoclonal

Molecular Weight

Predicted band size: 33 kDa;

Observed band size: 45-50 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

Q9NZQ7

Gene ID

29126 [NCBI]

Immunogen

Synthetic peptide within human PD-L1 aa 260-290 (Cytoplasmic).

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:2000
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:200-1:800
mIHC mIHC: Multiplex Immunohistochemical	1:1000

Purity	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified	Isotype	IgG

Appearance

Liquid

Formulation

Supplied in PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Verification Image

Western blot analysis of extracts from MDA-MB-231(lane 2(20ug) , U-87MG(lane 3(20ug) and HEK293(lane 4(20ug) using PD-L1 Antibody (HY-P84982) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P83730, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

Background

Function：Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201)|The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813410, PubMed:28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity)

Subcellular Localization：Cell membrane,Early endosome membrane,Recycling endosome membrane,Nucleus,Cell membrane,Endomembrane system,Secreted

Expression：
Tissue_Specificity: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes|Widely expressed, highest in lung, liver and pituitary and in various peripheral blood cells, including neutrophils and some subtypes of lymphoid and myeloid cells
Induction: Up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation. Up-regulated in B-cells activated by surface Ig cross-linking

Isoforms & Post-Translational Modification：Q9NZQ7 has four isomers: Q9NZQ7-1: 33275 Da (predicted); Q9NZQ7-2: 20246 Da (predicted); Q9NZQ7-3: 20454 Da (predicted); Q9NZQ7-4: 28050 Da (predicted).
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation (PubMed:28813410)

Subunit：Interacts with PDCD1 (PubMed:11015443, PubMed:18287011, PubMed:26602187)

RRID

AB_3719014

Database

SwissProt: Q9NZQ7 Human

Synonyms

Programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD antigen CD274; CD274 nanobody; PD-L1 nanobody;

Documentation

Select Batch:

Data Sheet (231 KB) SDS (251 KB)

COA (205 KB)

User Guide for Antibodies (1077 KB)